ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
Effective therapeutic options are still needed in neuroblastoma treatment. Here, the authors, through a comprehensive proteomics analysis, identify ATR as a potential therapeutic target of neuroblastoma and demonstrate the efficacy of the ATR inhibitor BAY1895344 in combination with the ALK tyrosine...
Saved in:
Main Authors: | Joanna Szydzik, Dan E. Lind, Badrul Arefin, Yeshwant Kurhe, Ganesh Umapathy, Joachim Tetteh Siaw, Arne Claeys, Jonatan L. Gabre, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/06e9a92a8a164615981fa91b32e6d409 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA
by: Demis Menolfi, et al.
Published: (2018) -
ATR harmony in Turkana
by: Manuela Noske
Published: (1996) -
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
by: Deng L, et al.
Published: (2018) -
ATR vowel harmony in Akposso
by: Coleen G. Anderson
Published: (1999) -
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
by: Barrows SM, et al.
Published: (2019)